What is Mycodev Group?
Mycodev Group operates at the intersection of biotechnology and material science, specializing in the production of high-purity chitosan. Unlike traditional sources that rely on animal-derived chitin, Mycodev utilizes a sophisticated fungal fermentation process to ensure a product free from common contaminants. This methodology allows for precise control over molecular weight and the degree of deacetylation, providing clients with a highly customizable and traceable material. Their market position is defined by a commitment to quality and consistency, catering to industries that demand rigorous standards for their development and manufacturing pipelines.
How much funding has Mycodev Group raised?
Mycodev Group has raised a total of $500K across 1 funding round:
Private Equity
$500K
Private Equity (2015): $500K with participation from New Brunswick Innovation Foundation
Key Investors in Mycodev Group
New Brunswick Innovation Foundation
The New Brunswick Innovation Foundation is a venture capital entity focused on supporting early-stage startups and innovative technologies, with a specific emphasis on enhancing the competitiveness of SMEs through strategic financial backing.
What's next for Mycodev Group?
With this major strategic investment, Mycodev Group is poised to transition from its current development phase into a broader commercial scaling operation. The company is expected to focus on optimizing its fermentation infrastructure to meet the increasing demand for high-purity biopolymers. Future growth will likely center on deepening its penetration into the pharmaceutical and biomedical sectors, where the demand for non-animal, traceable chitosan is particularly acute. By maintaining its focus on custom molecular specifications, the firm is well-positioned to secure long-term partnerships with enterprise-level clients seeking reliable, high-performance raw materials.
See full Mycodev Group company page
